Merck’s Keytruda faces 2028 biosimilar rights warning
Merck priced at $151.07 received a warning as Cipla’s U.S. subsidiary secured exclusive U.S. commercialization rights for Qilu Pharmaceutical’s proposed pembrolizumab biosimilar QL21.
Merck NYSE:MRK, the pharmaceutical and vaccine heavyweight priced at $151.07, got a blunt warning Thursday: Keytruda's biosimilar countdown is getting louder.
Cipla's U.S. subsidiary secured exclusive American commercialization rights to Qilu Pharmaceutical's proposed pembrolizumab biosimilar, QL21…